Testing obinutuzumab as ongoing treatment for brain and spinal cord lymphoma
Original title: Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage test in people, so it is not settled care yet.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
It tests a drug given after brain or spinal cord lymphoma responds to treatment.
Who this trial is for. This trial is for people with lymphoma in the brain or spinal cord. Their cancer went away or got smaller with treatment, and the trial tests obinutuzumab as ongoing care.
Where it stands. This trial has not reported results. It is testing whether obinutuzumab, a drug that acts on the immune system, helps after cancer responds. The answer is not in yet.
What this means, and what it doesn't
What it could mean: If this sounds like your situation, you can ask your care team about it. They know your case and can tell you if it is worth looking into.
What it doesn't mean: This does not mean the drug is proven to work this way. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you. It is not a cure.
Source: ClinicalTrials.gov, September 23, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.